Orplatna satraplatin: Preliminary Phase II data

Data from 16 evaluable patients in an ongoing, open-label Phase II trial of Orplatna plus Avastin bevacizumab and prednisone showed that 7 patients had a PSA decline, with a >=30% decline observed in...